INS and metabolic dysfunction-associated steatotic liver disease: This chronic inflammation impairs insulin signaling and drives metabolic disorders including type 2 diabetes mellitus (T2DM), hypertension, atherosclerosis, and metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as nonalcoholic fatty liver disease (NAFLD) (Peng et al., 2020).